Australia is evaluating the impact of potential US tariffs of 200% on pharmaceutical imports, Treasurer Jim Chalmers said, while reiterating that his nation’s subsidies for certain drugs are not up ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

Some GOP lawmakers and pro-trade lobbyists are quietly seeking to rein in the most extreme elements of the Trump ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

Trump’s latest two industrial sector tariffs—200 percent on pharmaceuticals and 50 percent on copper—have serious ...

The sector-specific tariffs are putting pressure on businesses and foreign nations as they try to navigate Trump’s constantly ...

Irish-made medicines heading to the US face steep new duties, raising alarm among patients, producers and investors on both ...

President Trump announced potential tariffs on imported pharmaceuticals by month's end, followed by semiconductor levies.

The US is Australia’s biggest export market for pharmaceuticals. If the tariffs go ahead, manufacturing could suffer.

President Trump on Tuesday threatened to impose up to 200 percent tariffs on pharmaceutical products imported into the U.S.